One such example involves INGAP peptide (INGAPpp), a structural homolog of REG3A derived from hamster, which has been evaluated in two randomized, placebo-controlled Phase II clinical trials targeting diabetes mellitus. Here, REG3A is linked to diabetes mellitus.